A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.